Last reviewed · How we verify
Prednisolone and Tobramycin
This combination uses prednisolone to suppress inflammation and tobramycin to provide topical antimicrobial coverage, typically for ocular infections or inflammatory conditions.
This combination uses prednisolone to suppress inflammation and tobramycin to provide topical antimicrobial coverage, typically for ocular infections or inflammatory conditions. Used for Ocular inflammation with bacterial infection risk, Post-operative ocular inflammation and infection prophylaxis.
At a glance
| Generic name | Prednisolone and Tobramycin |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Corticosteroid + Aminoglycoside antibiotic combination |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Prednisolone is a corticosteroid that reduces inflammation by suppressing immune responses and decreasing inflammatory mediator production. Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis. Together, they address both infectious and inflammatory components of ocular disease.
Approved indications
- Ocular inflammation with bacterial infection risk
- Post-operative ocular inflammation and infection prophylaxis
Common side effects
- Ocular irritation or discomfort
- Transient blurred vision
- Steroid-induced elevated intraocular pressure
- Allergic conjunctivitis
Key clinical trials
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children (NA)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisolone and Tobramycin CI brief — competitive landscape report
- Prednisolone and Tobramycin updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI